Clinical Trial Update Shows High Response Rate for Drug Combination

Inhibrx Biosciences published clinical results regarding its experimental cancer drug, INBRX-106, when combined with Merck KGaA's Keytruda. The combination achieved a confirmed objective response rate of 48.3% in a Phase 2 study of 68 patients with head and neck squamous cell carcinoma. This rate was compared to 26.5% for Keytruda alone. The announcement led to Inhibrx shares falling 8.8% to $110.45 following the results.

The study showed a notable difference in outcomes, including that four patients receiving the combination achieved a complete response, compared to none receiving Keytruda alone. The company is now considering a potential accelerated regulatory pathway for the combination therapy.